

Publication list

ORIGINAL ARTICLES

1. Jordan J, Sann U, Janton A, Gossmann J, Kramer W, Kachel HG, **Nowak A**, Scheuermann EH
Living kidney donors' long-term psychological status and health behavior after nephrectomy - a retrospective study
J Nephrol. 2004 Sep-Oct;17(5):728-35
2. Gossmann J, **Nowak A**, Kachel H. G., Jordan J, Sann U, Geiger H, Kramer W, Scheuermann EH
Long-term consequences of live kidney donation follow-up in 93% of living kidney donors in a single transplant center
Am J Transplant. 2005 Oct;5(10):2417-24
3. Hamscho N, **Nowak A**, Döbert N, Menzel C, Gossmann J, Berner U, Zaplatnikov K, Scheuermann EH, Grünwald F
Residual kidney function after donor nephrectomy. Assessment by 99mTc-MAG3-clearance
Nuklearmedizin. 2005 Oct;44(5):200-4
4. Hofmann L, Simon-Zoula S, **Nowak A**, Giger A, Vock P, Boesch C, Frey F, Vogt B.
BOLD-MRI for the assessment of renal oxygenation in humans: Acute effect of nephrotoxic xenobiotics
Kidney Int. 2006 Jul;70(1):144-50
5. Sollinger D, Mohaupt MG, **Wilhelm A**, Uehlinger D, Frey FJ, Eisenberger U
Arterial stiffness assessed by digital volume pulse correlates with comorbidity in patients with ESRD
Am J Kidney Dis. 2006 Sep;48(3):456-63
6. Breidhardt T, Socrates T, Noveanu M, Klima T, Heinisch C, Reichlin T, Potocki M, **Nowak A**, Tschung C, Arenja N, Bingisser R, Mueller C.
Impact and clinical prediction of worsening renal function in acute decompensated heart failure
Am J Cardiol. 2011 Mar1;107(5):730-5
7. **Nowak A**, Breidhardt T, Christ-Crain M, Bingisser R, Meune C, Tanglay Y, Heinisch C, Reiter M, Drexler B, Arenja N, Twerenbold R, Stolz D, Tamm M, Müller B, Müller C
Direct comparison of three natriuretic peptides for prediction of short- and long-term mortality in patients with community-acquired pneumonia
Chest. 2012 Apr;141(4):974-982
8. **Nowak A**, Breidhardt T, Dejung S, Christ-Crain M, Bingisser R, Drexler B, Meune C, Marono D, Mosimann T, Müller B, Müller C

Natriuretic Peptides for early prediction of acute kidney injury in community acquired pneumonia
Clin Chim Acta. 2013 Apr;18;419:67-72

9. Artunc F, **Nowak A**, Mueller C, Breidthardt T, Twerenbold R, Wagner R, Friedrich B
Plasma concentrations of the vasoactive peptides mid-regional pro-adrenomedullin, copeptin and c-terminal pro-endothelin 1 in hemodialysis patients: associated factors and prediction of mortality
PLoS One. 2014 Jan 22;9(1):e86148

10. Fauchère I, Moormann D, Maier W, Altweg L, Lüscher T, Grünenfelder J, **Nowak A**, Tüller D, Genoni M, Falk V, Hermann M
Rehabilitation After TAVI Compared To Surgical Aortic Valve Replacement
Int J Cardiol. 2014 May 15;173(3):564-6.

11. **Nowak A**, Friedrich B, Artunc F, Serra AL, Breidthardt T, Twerenbold R, Peter M, Potocki M, Mueller C
Prognostic value and link to atrial fibrillation of soluble Klotho and FGF23 in hemodialysis patients
PLoS One. 2014 Jul 3;9(7):e100688

12. Muskalla AM, Suter PM, Saur M, **Nowak A**, Hersberger M, Krayenbuehl PA
G-Protein Receptor Kinase 4 Polymorphism and Response to Antihypertensive Therapy
Clin Chem. 2014 Dec;60(12):1543-8

13. Artunc F, **Nowak A**, Müller C, Peter A, Heyne N, Häring H-U, Friedrich B
Mortality prediction using modern peptide biomarkers in hemodialysis patients – a comparative analysis
Kidney Blood Press Res. 2014;39(6):563-72

14. **Nowak A**, Artunc F, Serra A, Müller C, Pollock E, Krayenbuehl PA, Friedrich B
Sclerostin quo vadis? - is this a useful long-term mortality parameter in prevalent hemodialysis patients?
Kidney Blood Press Res. 2015;40(3):266-76

15. Weidmann ZM, Breidthardt T, Twerenbold R, Züsli C, **Nowak A**, von Eckardstein A, Erne P, Rentsch K, de Oliveira MT Jr, Gualandro D, Maeder MT, Rubini Gimenez M, Pershyna K, Stallone F, Haas L, Jaeger C, Wildi K, Puelacher C, Honegger U, Wagener M, Wittmer S, Schumacher C, Krivoshei L, Hillinger P, Osswald S, Mueller C
Prediction of mortality using quantification of renal function in acute heart failure
Int J Cardiol. 2015 Dec 15;201:650-7

16. Schmied C, **Nowak A**, Gruner C, Olinger E, Debaix H, Brauchlin A, Frank M, Reidt S, Monney P, Barbey F, Shah D, Namdar M
The value of ECG parameters as markers of treatment response in Fabry cardiomyopathy
Heart. 2016 Aug 15;102(16):1309-14

17. **Nowak A**, Mechtler TP, Desnick RJ, Kasper DC
Plasma LysoGb3: A useful biomarker for the diagnosis and treatment of Fabry disease heterozygotes
Mol Genet Metab. 2017 Jan - Feb;120(1-2):57-61

18. **Nowak A**, Boesch L, Andres E, Battegay E, Hornemann T, Schmid C, Bischoff-Ferrari H, Suter P, Krayenbuehl P-A
Effect of vitamin D3 on self-perceived fatigue: a double-blind randomized placebo-controlled trial.
Medicine, (Baltimore). 2016 Dec;95(52):e5353
19. **Nowak A**, Koch G, Huynh-Do U, Siegenthaler M, Marti H-P, Pfister M
Disease progression modeling to evaluate the effects of enzyme replacement therapy on kidney function in adult patients with the Classic phenotype of Fabry disease.
Kidney Blood Press Res. 2017;42(1):1-15
20. Saleh L, Tang J, Gawinecka J, Boesch L, Fraser WD, von Eckardstein A, **Nowak A**
Impact of a single oral dose of 100,000 IU vitamin D3 on vitamin D metabolite profiles in healthy adults with vitamin D insufficiency
Clin Chem Lab Med. 2017 Oct 26;55(12):1912-1921
21. **Nowak A**, Mechtler TP, Kasper DC, Desnick RJ
Correlation of Lyso-Gb3 levels in Dried Blood Spots and Sera from patients with Classic and Later-Onset Fabry Disease
Mol Genet Metab. 2017 Aug;121(4):320-324
22. **Nowak A**, Franzen DP, Haile SR, Mottet D, Bonani M, Kohler M, Krayenbuehl PA, Barbey F
Long-term follow-up of pulmonary function in Fabry disease: a multi-center observational study
PLoS One. 2017 Jul 25;12(7):e0180437
23. Lenders M, Oder D, **Nowak A**, Canaan-Kühl S, Arash-Kaps L, Drechsler C, Schmitz B, Nordbeck P, Hennermann JB, Kampmann C, Reuter S, Brand SM, Wanner C, Brand E
Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease.
J Intern Med. 2017 Sep;282(3):241-253
24. Siegenthaler M, U. Huynh-Do U, Krayenbuehl P, Pollock E, Widmer U, Debaix H, Olinger E, Frank M, Namdar M, Ruschitzka F, **Nowak A**
Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up
Int J Cardiol. 2017 Dec 15;249:261-267
25. Annema W, **Nowak A**, von Eckardstein A, Saleh L
Evaluation of the new restandardized Abbott Architect 25-OH Vitamin D assay in vitamin D-insufficient and vitamin D-supplemented individuals
J Clin Lab Anal. 2018 May;32(4):e22328
26. Menghini M, Prünke Ch, Krayenbuehl PA, **Nowak A**
Assessment of drusen and other retinal degenerative changes in patients with hereditary hemochromatosis
Retina. 2018 Mar;38(3):594-599

27. **Nowak A**, Mechtler TP, Hornemann T, Gawinecka J, Theswet E, Hilz MJ, Kasper DC
Genotype, phenotype and disease severity reflected by serum LysoGb3 levels in patients with Fabry disease
Mol Genet Metab. 2018 Feb;123(2):148-153
28. Ersözlü S, Desnick RJ, Huynh-Do U, Canaan-Kühl S, Barbey F, Genitsch V, Müller T, Cheetham M, Flammer A, Schaub S, **Nowak A**
Long-term outcomes of kidney transplantation in Fabry Disease
Transplantation. 2018 Nov;102(11):1924-1933
29. Franzen D, Haile S, Kasper D, Mechtler P, Flammer A, Krayenbuehl PA, **Nowak A**
Pulmonary involvement in Fabry disease: Effect of plasma globotriaosylsphingosine and time to initiation of enzyme replacement therapy
BMJ Open Respir Res. 2018 Apr 21;5(1):e000277
30. Kölling M, Seeger H, Haddad G, Kistler A, **Nowak A**, Faulhaber-Walter R, Kielstein J, Haller H, Fliser D, Mueller T, Wüthrich RP, Lorenzen JM
The circular RNA *ciRs-126* predicts survival in critically ill patients with acute kidney injury
Kidney Int Rep. 2018 Jun 2;3(5):1144-1152
31. Lenders M, Neusser L, Rudnicki M, Nordbeck P, Canaan-Kühl S, **Nowak A**, Cybulla M, Schmitz B, Lukas J, Wanner C, Brand S-M, Brand E
Dose-dependent impact of enzyme replacement therapy on anti-drug antibody titers and clinical outcomes in patients with Fabry disease
J Am Soc Nephrol. 2018 Dec;29(12):2879-2889
32. **Nowak A**, Giger RS, Krayenbuehl PA
Higher age at diagnosis of Hemochromatosis is the strongest predictor of the occurrence of Hepatocellular Carcinoma in the Swiss Hemochromatosis Cohort: a prospective longitudinal observational study
Medicine. 2018 Oct;97(42):e12886
33. Wussler D, Kozhuharov N, Sabti Z, Walter J, Strebel I, Scholl L, Miró O, Rosello X, MD; Martín-Sánchez FJ, Pockock SJ, **Nowak A**, MD; Badertscher P, Twerenbold R, Wildi K, Puelacher C, MD; Lavallaz J, Shrestha S, Flores D, Nestelberger T, Boeddinghaus J, Schumacher C, Goudev A, Pfister O, Breidhardt T, Mueller C
External Validation of the MEESSI Acute Heart Failure Risk Score
Ann Intern Med. 2019 Feb 19;170(4):248-256
34. Kleber M, Kozhuharov N, Sabti Z, Glatz B, Isenreich R, Wussler D, **Nowak A**, Twerenbold R, Badertscher P, Puelacher C, du Fay de Lavallaz J, Nestelberger T, Boeddinghaus J, Wildi K, Flores D, Walter J, Rentsch K, von Eckardstein A, Goudev A, Breidhardt T, Mueller C
Relative hypochromia and mortality in acute heart failure
Int J Cardiol. 2019 Jul 1;286:104-110
35. Gaisl T, **Nowak A**, Sievi NA, Gerard N, Clarenbach CF, Kohler M, Franzen D
Obstructive sleep apnea and quality of life in Fabry disease: a prospective parallel cohort study.

36. Kozhuharov N, Sabti Z, Wussler D, **Nowak A**, Badertscher P, Twerenbold R, Wildi K, Stallone F, Vogt F, Hilti J, Puelacher C, du Fay de Lavallaz J, Shrestha S, Flores D, Nestelberger T, Koechlin L, Boeddinghaus J, Zimmermann T, Walter J, Schumacher C, Rentsch K, von Eckardstein A, Keller DI, Goudev A, Pfister O, Breidhardt T, Mueller C
Prospective validation of N-terminal pro B-type natriuretic peptide cut-off concentrations for the diagnosis of acute heart failure.
Eur J Heart Fail. 2019 Jun;21(6):813-815
37. Oliveira JP, **Nowak A**, Barbey F, Torres M, Nunes JP, Teixeira-E-Costa F, Carvalho F, Sampaio S, Tavares I, Pereira O, Soares AL, Carmona C, Cardoso MT, Jurca-Simina IE, Spada M, Ferreira S, Germain DP
Fabry disease caused by the GLA p.Phe113Leu (p.F113L) variant: Natural history in males.
Eur J Med Genet. 2019 Jun 11:103703
38. **Nowak A**, Angelillo-Scherrer A, Betticher D, Dickenmann M, Guessous I, Juillerat P, Korte W, Neuner-Jehle S, Pfister O, Surbek D, Battegay E, Steurer J
Swiss Delphi study on iron deficiency.
Swiss Med Wkly. 2019 Jul 3;149:w20097
39. Heywood WE, Doykov I, Spiewak J, Hallqvist J, Mills K, **Nowak A**.
Global glycosphingolipid analysis in urine and plasma of female Fabry disease patients
Biochim Biophys Acta Mol Basis Dis. 2019 Oct 1;1865(10):2726-2735
40. Doykov ID, Heywood WE, Nikolaenko V, Śpiewak J, Hällqvist J, Clayton PT, Mills P, Warnock DG, Mills K, **Nowak A**
Rapid, proteomic urine assay for monitoring progressive organ disease in Fabry disease.
J Med Genet. 2019 Sep 13, pii: jmedgenet-2019-106030 [Epub ahead of print]
41. Wussler D, Kozhuharov N, Tavares Oliveira M, Bossa A, Sabti Z, **Nowak A**, Murray K, du Fay de Lavallaz J, Badertscher P, Twerenbold R, Shrestha S, Flores D, Nestelberger T, Walter J, Boeddinghaus J, Zimmermann T, Koechlin L, von Eckardstein A, Breidhardt T, Mueller C
Clinical Utility of Procalcitonin in the Diagnosis of Pneumonia.
Clin Chem. 2019 Dec;65(12):1532-1542
42. **Nowak A**, Huynh-Do U, Krayenbuehl PA, Beuschlein F, Schiffmann R, Barbey F
Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.
J Inherit Metab Dis. 2020 Mar;43(2):326-333.
43. Wanner C, Feldt-Rasmussen U, Jovanovic A, Linhart A, Yang M, Ponce E, Brand E, Germain DP, Hughes DA, Jefferies JL, Martins AM, **Nowak A**, Vujkovic B, Weidemann F, West ML, Ortiz A
Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis.
ESC Heart Fail. 2020 Jun;7(3):825-834.

44. Sweda R, Sabti Z, Strebel I, Kozhuharov N, Wussler D, Shrestha S, Flores D, Badertscher P, Lopez-Ayala P, Zimmermann T, Michou E, Gualandro DM, Häberlin A, Tanner H, Keller DI, **Nowak A**, Pfister O, Breidhardt T, Mueller C, Reichlin T
Diagnostic and Prognostic Values of the QRS-T Angle in Patients With Suspected Acute Decompensated Heart Failure.
ESC Heart Fail. 2020 May 26 in press

REVIEW ARTICLES

1. Göksu Y, Hofbauer G, Serra AL, **Nowak A**
Maligne Hauterkrankungen bei organtransplantierten Patienten
Praxis (Bern 1994). 2012 Jan 18;101(2):75-83
2. Mayer F, Hofbauer G, **Nowak A**
Frühe kutane Karzinogenese bei organtransplantierten Patienten
Praxis (Bern 1994). 2012 Oct 31;101(22):1401-9
3. **Nowak A**, Krayenbühl P.-A
Extraskelettale Vitamin-D-Wirkungen
Leading Opinions. 2013/2; 8-12
4. **Nowak A**, L. Serra AL
Abklärung der Proteinurie
Praxis (Bern 1994). 2013 Jun 19;102(13):797-802.
5. Hakman P, Vallelian F, **Nowak A**
Riesenzellarteriitis
Praxis (Bern 1994). 2013 Jun 5;102(12):703-8
6. Müggler A, Iseli SM, Meindl-Fridez C, **Nowak A**, Brunckhorst CB
AV-Knoten-Reentry-Tachykardie
Praxis (Bern 1994). 2013 Sept 1;102(19):1155-64
7. **Nowak A**, Göhner K, Cohen C
Caplan-Syndrom: eine untypische Differentialdiagnose des „pulmo-renalen“ Syndroms
Praxis (Bern 1994). 2014 Feb 26;103(5):279-84
8. Pollock E, **Nowak A**
The cardio-renal problem
Swiss Med Wkly. 2014 Dec 4;144:w14051
9. Steinack C, Gaspert A, Kovacs R, **Nowak A**
Morbus Fabry: Selten, aber nicht zu verpassen. CME
Praxis (Bern 1994). 2015 Jul;104(14):719-29
10. Rodieux F, Pfister M, van den Anker J, Rohrbach M, Schuknecht B, Gaspert A, Palla A, **Nowak A**
Unexplained peripheral neuropathic pain and/or unexplained stroke in young patients - think about Fabry disease
Swiss Archives of Neurology, Psychiatry and Psychotherapy. 2016 Apr;167(3):74-80
11. Schreiner F, Krayenbühl PA, Goede J, **Nowak A**
Approach to the Patient with Elevated Serum Ferritin
Praxis (Bern 1994). 2016 May 11;105(10):543-51
12. **Nowak A**
Linksherzhypertrophie – denken Sie an einen Morbus Fabry
Cardiovascular Medicine. 2016;19(05)

13. Krüger S, **Nowak A**, Lang K, Müller TC
Case report on General anesthesia and Fabry disease
A A Case Rep. 2017 May 15;8(10):247-249
14. Battegay E, Cheetham M, Holzer BM, **Nowak A**, Schmidt D, Rampini S
Multimorbiditätsmanagement im Alltagsdilemma
Der Internist. 2017 DOI 10.1007/s00108-017-0200-9
15. Lüthi L, Andreas Kistler A, **Nowak A**
Hyperkaliämie bei Patienten mit chronischer Hämodialyse (exotische Ursache, lebensbedrohliche Folge)
Praxis (Bern 1994). 2017 Jun;106(12):679
16. Lecheler L, Richter M, Franzen DP, Rampini SK, Cheetham M, Jenewein J, Battegay E, **Nowak A**
The frequent and underrecognized co-occurrence of Acute Exacerbated Chronic Obstructive Pulmonary Disease and Depression warrants screening: a systematic review
Eur Respir Rev. 2017 Jun 14;26(144)
17. Müller S, Tanner F, Gruner C, Ruschitzka F, Flammer A, **Nowak A**
Morbus Fabry - Eine seltene, aber wichtige Ursache einer Linksventrikulären Hypertrophie
Cardiovasc Med. 2018;21(09):212-217
18. Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, **Nowak A**, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ
European expert consensus statement on therapeutic goals in Fabry disease.
Mol Genet Metab. 2018 Jul;124(3):189-203
19. Tamo R, Rohrbach M, Baumgartner M, Beuschlein F, Nowak A
The basics of lysosomal storage diseases
Ther Umsch, 2018 Nov;75(4):199-207
20. Tamo R, Hochuli M, Beuschlein F, **Nowak A**
Morbus Gaucher – ein Überblick über eine Sphingolipidose
Ther Umsch, 2018 Nov;75(4):209-214
21. Tamo R, Zweifel S, Beuschlein F, **Nowak A**
Morbus Fabry – das Porträt einer seltenen Erkrankung
Ther Umsch, 2018 Nov;75(4):217-224
22. **Nowak A**
Stoffwechselkrankheiten
Ther Umsch, 2018 Nov;75(4):197

23. Mensing B, **Nowak A**, Zweifel S, Terracciano L, Bernsmeier C, Filipowicz Sinnreich M

Morbus Wilson oder hepatolentikuläre Degeneration

Ther Umsch, 2018 Nov;75(4):241-248

24. Ersözlü S, **Nowak A**

Morbus Fabry kann die Ursache einer unklaren Linksherzhypertrophie sein

info@herz+gefäss. 2019 Jan

25. Germain DP, Elliott PM, Falissard B, Fomin VV, Hilz MJ, Jovanovic A, Kantola I, Linhart A, Mignani R, Namdar M, **Nowak A**, Oliveira JP, Pieroni M, Viana-Baptista M, Wanner C, Spada M

The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts

Mol Genet Metab Rep. 2019 Feb 6;19:100454

26. Tatalovic M, Lehmann R, Cheetham M, **Nowak A**, Battegay E, Rampini SK.

Management of hyperglycaemia in persons with non-insulin-dependent type 2 diabetes mellitus who are started on systemic glucocorticoid therapy: a systematic review.

BMJ Open. 2019 Jun 1;9(5):e028914.

BOOKS

Barbey F, **Nowak A**

Die Fabry Krankheit erklären. Von Ärzten für Kinder Verpasst! Medikidz 14 Basil Street, London 2017.

LETTERS

1. **Nowak A**, Siegenthaler M, Namdar M, Ruschitzka F

Reply: Impact of Cardio-Renal Syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up.

Int J Cardiol. 2018 May 1;258:206